71783-54-5

Usage

Uses

Used in Pharmaceutical Industry:
METHYL BROMO(4-FLUOROPHENYL)ACETATE is used as an intermediate in the synthesis of various pharmaceuticals for its effectiveness in organic synthesis reactions.
Used in Agrochemical Industry:
METHYL BROMO(4-FLUOROPHENYL)ACETATE is used as an intermediate in the synthesis of agrochemicals, contributing to the development of products for agricultural applications.
Used in Organic Compounds Synthesis:
METHYL BROMO(4-FLUOROPHENYL)ACETATE is used as a reagent in the synthesis of other organic compounds, playing a crucial role in the production of a wide range of products.

Upstream product

• 459-04-1 4-Fluorophenylacetyl chloride 
• 219564-79-1 methyl 2-diazo-2-(4-fluorophenyl)acetate 
• 67-56-1 methanol 
• 29270-33-5 2-bromo-2-(4-fluorophenyl)acetic acid 
• 405-50-5 p-Fluorophenylacetic acid 
• 34837-84-8 4-fluorobenzeneacetic acid methyl ester 
• 32222-45-0 4-fluoromandelic acid 
• 127709-19-7 methyl 4-fluoro-α-hydroxyphenylacetate 

Downstream Products

• 77053-69-1 (1R,2S)-1-(4-Fluoro-phenyl)-cyclopropane-1,2-dicarboxylic acid dimethyl ester 
• 191033-99-5 4-[(4-fluoro-phenyl)-methoxycarbonyl-methyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 845280-54-8 [2-((4R,6R)-6-tert-Butoxycarbonylmethyl-2,2-dimethyl-[1,3]dioxan-4-yl)-ethylamino]-(4-fluoro-phenyl)-acetic acid methyl ester 
• 100638-27-5 2-(4-fluorophenyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazine 
• 186025-96-7 methyl α-(4-fluoro)-benzylthio-4-fluorophenylacetate 
• 1397007-09-8 C₁₃H₁₈FO₅P 
• 1194032-78-4 (4-fluoro-phenyl)-(3-hydroxy-propylamino)-acetic acid methyl ester 
• 122340-51-6 C₁₄H₁₁FN₂O 
• 1186200-76-9 methyl 2-(acetylthio)-2-(4-fluorophenyl)acetate 
• 1634722-03-4 C₂₁H₁₇FN₂O 
• 1634721-96-2 C₁₇H₁₅FN₂O 
• 1634722-01-2 C₁₉H₁₇FN₂O₃ 
• 1057221-63-2 3-(4-fluorophenyl)quinoxalin-2(1H)-one 
• 1634721-94-0 C₂₅H₂₃FN₂O₃ 

Relevant academic research and scientific papers

Manganese/bipyridine-catalyzed non-directed C(sp3)–H bromination using NBS and TMSN3

A Mn(II)/bipyridine-catalyzed bromination reaction of unactivated aliphatic C(sp3)?H bonds has been developed using N-bromosuccinimide (NBS) as the brominating reagent. The reaction proceeded in moderate-to-good yield, even on a gram scale. The introduced bromine atom can be converted into fluorine and allyl groups.

Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions

Nuclear factor erythroid 2-related factor 2 (NRF2) is a pleiotropic transcription factor which regulates the constitutive and inducible transcription of a wide array of genes and confers protection against a variety of pathologies. Directly disrupting Kelch-like ECH-associated protein 1 (KEAP1)-NRF2 protein-protein interaction (PPI) has been explored as a promising strategy to activate NRF2. We reported here the first identification of a series of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 inhibitors. Our efforts led to the potent small molecule KEAP1-NRF2 inhibitor, 20c, which exhibited a Kd of 24 nM to KEAP1 and an IC50 of 75 nM in disrupting KEAP1-NRF2 interaction. Subsequent biological studies provided consistent evidence across mouse macrophage cell-based and in vivo models that 20c induced NRF2 target gene expression and enhanced downstream antioxidant and anti-inflammatory activities. Our study not only demonstrated that small molecule KEAP1-NRF2 PPI inhibitors can be potential preventive and therapeutic agents for diseases and conditions involving oxidative stress and inflammation but also enriched the chemical diversity of the KEAP1-NRF2 inhibitors.

Bromination of α-Diazo Phenylacetate Derivatives Using Cobalt(II) Bromide

A method for the bromination of α-diazo phenylacetate derivatives using cobalt(II) bromide is described. This bromination reaction features a short reaction time, broad substrate scope, operational simplicity, acid-free conditions, and gram-scalability. (Figure presented.).

Diastereo- And Enantioselective Synthesis of Quaternary α-Amino Acid Precursors by Copper-Catalyzed Propargylation

A diastereo- and enantioselective propargylic substitution reaction between propargylic carbonates and α-substituted nitroacetates catalyzed by a Cu-pybox complex is described. This method allows the preparation of a series of non-proteinogenic quaternary α-amino acid precursors featuring two contiguous stereogenic centers and a terminal alkyne moiety in high yields with good to excellent diastereo- and enantioselectivities in most cases. The propargylated adducts were elaborated into a diverse set of quaternary α-amino acid derivatives.

New 4-aryl-1,3,2-oxathiazolylium-5-olates: Chemical synthesis and photochemical stability of a novel series of S-nitrosothiols

S-nitrosothiols (RSNOs) remain one of the most popular classes of NO-donating compounds due to their ability to release nitric oxide (NO) under non-enzymatic means whilst producing an inert disulphide by-product. However, alligning these compounds to the different biological fields of NO research has proved to be problematic due to the inherent instability of such compounds under a variety of conditions including heat, light and the presence of copper ions. 1,3,2-Oxathiazolylium-5-olates (OZOs) represent an interesting subclass of S-nitrosothiols that lock the –SNO moiety into a five membered heterocyclic ring in an attempt to improve the compound's overall stability. The synthesis of a novel series of halogen-containing OZOs was comprehensively studied resulting in a seven-step route and overall yields ranging between 21 and 37%. The photochemical stability of these compounds was assessed to determine if S-nitrosothiols locked within these mesoionic ring systems can offer greater stability and thereby release NO in a more controllable fashion than their non-cyclic counterparts.

Synthesis of Quinolines by Visible-Light Induced Radical Reaction of Vinyl Azides and α-Carbonyl Benzyl Bromides

A visible-light induced radical reaction of vinyl azides and α-carbonyl benzyl bromides was developed, which provides an efficient route to polysubstituted quinolines via a C-C and C-N bond formation sequence.

MINERALOCORTICOID RECEPTOR ANTAGONISTS

Disclosed are the compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, which are useful for treating aldosterone-mediated diseases. The processes for preparing compounds of the Formula (I), the use for the therapy and prophyl

PROCESS FOR PRODUCTION OF THIOPHENE COMPOUND AND INTERMEDIATE THEREOF

To provide a novel process for producing a 2-aryl-3-hydroxy-4-substituted carbonyl thiophene compound or an intermediate thereof useful as an intermediate for production of medicines and agricultural chemicals. A 2-aryl acetate compound represented by the formula (1): wherein R1 is an aryl group or the like, R4 is a C1-3 alkyl group or the like, and X is a leaving group, is reacted with a thioacetic acid compound to form a thioacetyl compound (3), the thioacetyl compound (3) is reacted with a vinyl ketone compound to form a γ-ketosulfide compound (5), which is cyclized under basic conditions to form a dihydrothiophene compound (6), and the dihydrothiophene compound (6) is oxidized by using an oxidizing agent to produce a 2-aryl-3-hydroxy-4-substituted carbonyl thiophene compound (7).

Imidazolidinone Derivatives as 11B-HSD1 Inhibitors

Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein A and R1 to R4 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.

Hepatoselectivity of statins: Design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors

4-Sulfamoyl pyrroles were designed as novel hepatoselective HMG-CoA reductase inhibitors (statins) to reduce myalgia, a statin-induced adverse effect. The compounds were prepared via a [3 + 2] cycloaddition of a Muenchnone with a sulfonamide-substituted alkyne. We identified compounds with greater selectivity for hepatocytes compared to L6-myocytes than rosuvastatin and atorvastatin. There was an inverse correlation of myocyte potencies and C log P values. A number of analogs were effective at reducing cholesterol in acute and chronic in vivo models but they lacked sufficient chronic in vivo activity to warrant further development.